|
WO0115705A1
|
|
Use of fructose-1,6-diphosphate as an inotrope drug for cardiopulmonary bypass surgery
|
|
WO0025796A1
|
|
Treatment of asthma with fructose-1,6-diphosphate
|
|
US6076528A
|
|
Injection of fructose-1,6-diphosphate (FDP) prior to coronary artery bypass grafting surgery
|
|
US6011017A
|
|
Method of reducing pulmonary hypertension and atrial fibrillation after surgery using cardiopulmonary bypass
|
|
WO9836743A1
|
|
Neuroprotective poly-guanidino compounds which block presynaptic n and p/q calcium channels
|
|
EP0927557A1
|
|
Use of fructose diphosphate to reduce cyclosporine dosages after organ transplantation
|
|
US5944020A
|
|
Use of fructose-1 6-diphosphate as an inotrope drug after cardiopulmonary bypass surgery
|
|
US6074658A
|
|
Treatment of sickle cell anemia crises with fructose-1, 6-diphosphate as an analgesic drug
|
|
AU7642996A
|
|
Partially lyophilized fructose-1,6-diphosphate (FDP) for injection into humans
|
|
EP0982033A2
|
|
Use for fructose-1,6-diphosphate (FDP) in the manufacture of medicaments
|
|
EP0814087A2
|
|
Partially lyophilized fructose-1,6-diphosphate (FDP) for injection into humans
|
|
US5731291A
|
|
Partially lyophilized fructose-1,6-diphosphate (FDP) for injection into humans
|
|
WO9728803A1
|
|
Hydroxynonyladenine analogs with enhanced lipophilic and anti-ischemic traits
|
|
US5587397A
|
|
Reduction of elevated blood lactate using twice-daily dichloroacetate
|
|
CA2145618A1
|
|
Use of Aminoglycosides to Protect Against Excitotoxic Neuron Damage
|
|
US5491146A
|
|
Hydroxylated erythro-hydroxynonyladenines and related analogs
|
|
US5677288A
|
|
Use of aminoglycosides to protect against excitotoxic neuron damage
|
|
US5206264A
|
|
Use of disulfiram to prevent cardiovascular damage
|
